William Blair Downgrades AVEO Pharmaceuticals (AVEO) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
Stifel Nicolaus Upgrades AVEO Pharmaceuticals (AVEO) to Hold
May 3, 2013 8:37 AM EDTStifel Nicolaus upgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Sell to Hold.
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $2.65 yesterday, with a 52 week range of $2.25-$14.08.... More
RBC Capital Downgrades AVEO Pharmaceuticals (AVEO) to Sector Perform
May 3, 2013 7:15 AM EDTRBC Capital downgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Outperform to Sector Perform.
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $2.65 yesterday, with a 52 week range of $2.25-$14.08.... More
JPMorgan Downgrades AVEO Pharmaceuticals (AVEO) to Neutral
May 2, 2013 2:05 PM EDTJPMorgan downgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Overweight to Neutral.
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more ratings news on AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $5.26 yesterday, with a 52 week range of $5.07-$14.08.... More
AVEO Oncology (AVEO) Resume Trading, Immediatly Halted
May 2, 2013 1:21 PM EDTAVEO Oncology (NASDAQ: AVEO) resumed trading and was immediately halted on a circuit breaker. Shares down 57%... More
BMO Capital Downgrades AVEO Pharmaceuticals (AVEO) to Underperform
May 2, 2013 12:58 PM EDTBMO Capital downgraded AVEO Pharmaceuticals (NASDAQ: AVEO) from Market Perform to Underperform with a price target of $1.00 (from $8.00).
For an analyst ratings summary and ratings history on AVEO Pharmaceuticals click here. For more... More
AVEO Oncology's (AVEO) Tivozanib Receives Disappointing News from FDA Oncologic Drugs Advisory Committee
May 2, 2013 12:57 PM EDTAVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. today reported that the U.S. Food and Drug Administrations (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled trial (13 to 1, 0 abstentions).
While we are disappointed... More
